16th week of 2012 patent applcation highlights part 38 |
Patent application number | Title | Published |
20120093769 | Stem Cell Targeting with Dock-and-Lock (DNL) Complexes - Disclosed herein are compositions and methods of use of dock and lock (DNL) complexes comprising a first antibody or fragment that binds to a stem cell antigen and a second antibody or fragment thereof that binds to an antigen on a diseased or damaged tissue or organ. The DNL complexes are of use for targeting stem cells to diseased or damaged organs or tissues and may be used to treat a variety of diseases or conditions that are responsive to stem cell therapy. | 2012-04-19 |
20120093770 | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases - The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated form of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity. | 2012-04-19 |
20120093771 | METHOD FOR PREPARING A HARDENED CALCIUM SULFATE DIHYDRATE BLOCK AND USE THEREOF - The present invention provides a technique for prolonging the working time and setting time of a calcium sulfate hemihydrate paste by mixing calcium sulfate hemihydrate powder with an aqueous solution containing phosphate ions, so that the paste is suitable for operation and the resultant hardened calcium sulfate dihydrate block from the paste has an improved mechanical strength. | 2012-04-19 |
20120093772 | VECTORS FOR DELIVERY OF LIGHT SENSITIVE PROTEINS AND METHODS OF USE - Provided herein are compositions and methods for gene and etiology-nonspecific and circuit-specific treatment of diseases, utilizing vectors for delivery of light-sensitive proteins to diseased and normal cells and tissues of interest. | 2012-04-19 |
20120093773 | Compositions for Bacterial Mediated Gene Silencing and Methods of Using Same - Methods are described for the delivery of one or more small interfering RNAs (siRNAs) to a eukaryotic cell using a bacterium. Methods are also described for using this bacterium to regulate gene expression in eukaryotic cells using RNA interference, and methods for treating cancer of cell proliferative disorders. The bacterium includes one or more siRNAs or one or more DNA molecules encoding one or more siRNAs. Vectors are also described for use with the bacteria of the invention for causing RNA interference in eukaryotic cells. | 2012-04-19 |
20120093774 | AUXOTROPHIC RECOMBINANT BCG STRAIN PASTEUR AND USE THEREOF IN THE CONTROL OF HUMAN INFECTIONS CAUSED BY PARASITES - The present invention relates to a vaccinal strain of recombinant BCG | 2012-04-19 |
20120093775 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CIRRHOSIS AND LIVER FIBROSIS - The invention provides a method for the treatment of cirrhosis and liver fibrosis by the use or viral vectors containing the gene encoding IGF-I. The invention discloses both parvoviral vectors and SV40-based vectors as well uses thereof for the treatment of cirrhosis and gene therapy and methods for the preparation of said viral vectors. | 2012-04-19 |
20120093776 | METHODS FOR TREATING DISEASES USING A BONE MORPHOGENETIC PROTEIN - Described herein are methods, uses, and pharmaceutical compositions for treating heart disease that include a bone morphogenetic protein (BMP). In addition, described herein are methods, uses, and compositions for preventing or slowing fibrosis in diseased or injured tissue, and/or for preventing or slowing cell death in diseased or injured tissue. | 2012-04-19 |
20120093777 | COMPOSITIONS COMPRISING VIRUSES AND METHODS FOR CONCENTRATING VIRUS PREPARATIONS - A composition is disclosed comprising virus in a formulation comprising a polyhydroxy hydrocarbon buffered to maintain a pH in a range from about 7 to about 8.5 at a temperature in the range from about 2° C. to 27° C. Methods for concentrating and purifying virus preparations are also disclosed. | 2012-04-19 |
20120093778 | SIMIAN ADENOVIRUS NUCLEIC ACID AND AMINO ACID SEQUENCES, VECTORS CONTAINING SAME, AND METHODS OF USE - A recombinant vector comprises simian adenovirus sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses simian adenovirus gene(s) is also disclosed. Methods of using the vectors and cell lines are provided. | 2012-04-19 |
20120093779 | COMPLEX MICROBIAL PREPARATION FOR TREATING DIABETES AND PREPARATIVE METHOD AND USE THEREOF - A complex microbial preparation comprises (in vol. %): | 2012-04-19 |
20120093780 | PROCESS FOR PRODUCING POXVIRUSES AND POXVIRUS COMPOSITIONS - The present invention relates to compositions and pharmaceutical compositions comprising poxviruses and more particularly extracellular enveloped viruses. The present invention also relates to a process for producing poxviruses and poxviruses obtained thereof. Moreover, the present invention also relates to the use of said poxvirus and said composition for the preparation of a medicament. | 2012-04-19 |
20120093781 | HUMAN MAST CELL LINE AND USES THEREOF - The subject invention pertains to the development of a novel human mast cell line, USF-MC1. USF-MC1 is a mast cell precursor present in human umbilical cord blood (HUCB) that may be sustained in culture in the absence of exogenous cytokines to serve as a convenient experimental model of human mast cell activation. The SCF-independent human mast cell line USF-MC1 responds to IgE-mediated and IgE-independent stimuli in a way comparable to that of LAD2. USF-MC1 cells are useful for investigation of IgE-mediated activation mechanisms of human mast cells, contributing to the development of effective treatments for allergic disorders and other disorders. The subject invention provides a ready source of human mast cells for research, including pharmacological studies for the screening of various agents, and toxicologic, e.g., for the cosmetic and pharmaceutical industries. The mast cells can also be used as biofactories, for the large-scale production of biomolecules. | 2012-04-19 |
20120093782 | Enhanced Hematopoietic Stem Cell Engraftment - The invention relates to improved products, processes, and therapeutic methods relating to hematopoietic stem cells and hematopoietic stem cell transplantation. Included are methods for improving transplant efficiency of cord blood units comprising use of mixtures of expanded CD34 | 2012-04-19 |
20120093783 | USE ADIPOSE TISSUE-DERIVED REGENERATIVE CELLS IN THE MODULATION OF INFLAMMATION IN THE PANCREAS AND IN THE KIDNEY - Aspects of the present invention relate to the field of medicine, specifically, the effect of adipose tissue and its components on modulating inflammation. | 2012-04-19 |
20120093784 | COMPOSITIONS AND METHODS FOR CONTROLLING STEM CELL AND TUMOR CELL DIFFERENTIATION, GROWTH, AND FORMATION - The present invention relates to the use of self-assembling peptide amphiphiles to prevent tumor formation by transplanted stem cells. The present invention further relates to the use of self-assembling peptide amphiphiles to treat cancers. | 2012-04-19 |
20120093785 | HUMAN ARTIFICIAL CHROMOSOME (HAC) VECTOR - The present invention relates to a human artificial chromosome (HAC) vector and a method for producing the same. The present invention further relates to a method for introducing foreign DNA using a human artificial chromosome vector and a method for producing a cell which expresses foreign DNA. Furthermore, the present invention relates to a method for producing a protein. | 2012-04-19 |
20120093786 | TREATMENT OF LIMB ISCHEMIA - The present invention uses neural stem cells in the manufacture of a medicament for the treatment of a patient suffering peripheral arterial disease. The invention is particularly suited for treating limb ischemia or Buerger's disease. | 2012-04-19 |
20120093787 | METHODS AND COMPOSITIONS FOR INHIBITING VIRAL ENTRY INTO CELLS - Disclosed herein are methods and compositions for inhibiting viral entry into cells. | 2012-04-19 |
20120093788 | PROTEASE FOR WOUND CONDITIONING AND SKIN CARE - We have identified by molecular cloning a protease which originates from the larvae of | 2012-04-19 |
20120093789 | Methods of Modulating Smooth Muscle Cell Proliferation and Differentiation - The present disclosure provides methods of inducing smooth muscle cell differentiation. The present disclosure provides genetically modified cells comprising exogenous miR-143 and/or miR-145 nucleic acids; and artificial tissues comprising the genetically modified cells. The present disclosure provides methods and compositions for reducing pathological angiogenesis. The present disclosure provides methods of inducing therapeutic angiogenesis. The present disclosure provides methods, compositions, and devices for inhibiting vascular smooth muscle cell proliferation. | 2012-04-19 |
20120093790 | HLA HOMOZYGOUS CELLS AND METHODS OF USE THEREOF - The present invention provides methods of generating a mammalian cell that is homozygous at a locus of interest, as well as cells made by the method. The present invention further provides methods of using the cells. | 2012-04-19 |
20120093791 | STIMULATION OF INNATE IMMUNITY WITH AN ANTIGEN FROM BACTERIAL ORIGIN - There is provided a method of attenuating a respiratory infection in a subject, use of a composition for the manufacture of a medicament and a composition for treating respiratory infections comprising a preparation of | 2012-04-19 |
20120093792 | IMMUNOTHERAPY FOR PANCREATIC CANCER - The present invention provides an immunotherapeutic agent and immunotherapy allowing the extension of the survival time of patients with pancreatic cancer. The immunotherapy of the present invention is characterized by comprising the steps of culturing peripheral blood lymphocytes of a patient with pancreatic cancer by stimulating the lymphocytes with an anti-CD3 antibody and an anti-CD52 antibody, thereby to obtain an immunotherapeutic agent, and administering at least four infusions of the resultant immunotherapeutic agent to the same patient, wherein each of the infusions of the immunotherapeutic agent comprises at least 15×10 | 2012-04-19 |
20120093793 | Methods of Preventing Platelet Alloimmunization and Alloimmune Platelet Refractoriness and Induction of Tolerance in Transfused Recipients - Methods and compositions for the prevention or reduction of platelet transfusion associated complications are provided. Methods are provided to modify donor platelets prior to transfusion to prevent or reduce alloimmune platelet refractoriness. | 2012-04-19 |
20120093794 | Methods for Treating Pompe Disease - The present invention provides methods for treating Pompe disease in a subject by administering to the subject a therapeutically effective amount of a fusion protein which includes human acid alpha-glucosidase (GAA), or a fragment thereof, and a lysosomal targeting domain. The lysosomal targeting domain binds the human cation-independent mannose-6-phosphate receptor in a mannose-6-phosphate-independent manner. | 2012-04-19 |
20120093795 | COMPOUNDS TARGETING THE CATION-INDEPENDENT MANNOSE 6-PHOSPHATE RECEPTOR - The invention relates to conjugates of products of interest and of compounds targeting the cation-independent mannose 6-phosphate receptor with a high affinity. The invention also relates to their applications, for instance in enzyme replacement therapies. | 2012-04-19 |
20120093796 | NOVEL USE OF EC-SOD AND METHOD FOR PREPARING THEREOF - The present invention relates to compositions for preventing or treating angiogenesis-mediated diseases or allergic diseases which contain, as an active ingredient, an EC-SOD protein or a vector having a polynucleotide encoding thereof. The EC-SOD protein or the vector having a polynucleotide encoding the EC-SOD protein has the effect on inhibiting angiogenesis by inhibiting the expression of VEGF and MMP-9 which induce angiogenesis. Therefore, the EC-SOD protein or the vector may be useful for preventing or treating angiogenesis-mediated diseases. And the EC-SOD protein or the vector having a polynucleotide encoding said EC-SOD protein also has the effect on inhibiting over-differentiation of Th2 cells which cause allergic diseases, inhibiting transcription factor (NF-κ B), and reducing degranulation of human mast cells. Accordingly, the EC-SOD protein or the vector may be useful for preventing or treating allergy diseases. In addition, the inventive method for preparing an EC-SOD protein may be used in preparing an EC-SOD protein having the activity on a large scale. Therefore, the inventive method may be useful industrially. | 2012-04-19 |
20120093797 | COMBINED USE OF CREATINE PHOSPHATE AND CREATINE PHOSPHOKINASE FOR TREATMENT OF ARTERIOSCLEROSIS - Disclosed are a creatine phosphate (CP) and creatine phosphokinase (CPK) in association for use in the treatment of an atherosclerotic plaque present in the wall of an artery of a patient. | 2012-04-19 |
20120093798 | Methods for Treatment of Stroke or Cerebrovascular - Methods of using an ET | 2012-04-19 |
20120093799 | RECOMBINANTLY MODIFIED PLASMIN - Polynucleotides and polypeptides relating to a recombinantly modified plasmin(ogen) molecule are provided. The plasmin(ogen) molecule has a single kringle domain N-terminal to the activation site present in the native human plasminogen molecule, combined such that no foreign sequences are present, and exhibits lysine-binding and significant enzymatic characteristics associated with the native enzyme | 2012-04-19 |
20120093800 | PLANT EXTRACT COMPRISING STATINS AND PREPARATION TECHNIQUES AND USES THEREOF - A plant extract comprising one or more statins and being substantially free of polar compounds that affect pharmacokinetics of a drug in a subject is provided. Also provided is a method of preparing an extract comprising the step of removing polar compounds that affect pharmacokinetics of a drug in a subject from a plant material containing one or more statins. | 2012-04-19 |
20120093801 | TARGETED DELIVERY OF THERAPEUTIC AGENTS WITH LYOPHILIZED MATRICES - Embodiments of surgical grafts, and methods, for the delivery of therapeutic agents to a target tissue via acellular matrices, are described. In some embodiments, nonviable matrices are successful in preventing or lessening adhesion formation by guiding tissue repair and remodeling, while also providing the target tissue with therapeutic agents that can act as repair and remodeling factors. An exemplary method to modulate flexor tendon healing and provide elimination or reduction of fibrotic adhesions involves loading a freeze-dried flexor digitorum longus allograft with recombinant adeno-associated viral (rAAV) vectors for the targeted and transient expression of growth/differentiation factor 5 (GDF5). | 2012-04-19 |
20120093802 | BIOACTIVE COMPOSITION INCLUDING STABILIZED PROTEIN AND PROCESS FOR PRODUCING THE SAME - A bioactive composition includes a porous hydrogel matrix. At least one protein is immobilized in the porous hydrogel matrix forming a hydrogel protein composite that is stable in an organic solvent. A process for stabilizing a bioactive composition includes the steps of: forming hydrogel matrix pores around protein molecules and reducing a water content within the hydrogel matrix pores forming a hydrogel protein composite that is stable in an organic solvent. | 2012-04-19 |
20120093803 | MEANS AND METHODS OF STERILIZATION OF BIOFUNCTIONAL COMPOSITIONS - The present invention, inter alia, relates to a closed sterilized container comprising at least one carrier which is a stabilizer; and at least one biomolecule reversibly attached to the carrier, wherein said carrier partially or completely covers the attached biomolecules and wherein said at least one carrier is selected from the group consisting of (poly)peptides such as dipeptides or tripeptides, amino acids, polyalcohols, polyethyleneglycols, ionic liquids, compatible solutes, saponins and a mixture thereof. The invention also relates to methods for producing sterilized containers according to the invention and uses thereof. | 2012-04-19 |
20120093804 | Concatamers for Immunemodulation - The invention relates to a polymeric, non-coding nucleic acid molecule for modulation of the activity of the human and animal immune system as well as a method for the manufacture thereof and a vaccine, comprising the polymeric, non-coding nucleic acid molecule, wherein polymeric, non-coding nucleic acid molecules may be understood as non-coding nucleic acid molecules, comprising at least four covalently bound molecules (tetramer) or are assemblies of more non-coding nucleic acid molecules (high molecular polymers) which are covalently bound to each other. | 2012-04-19 |
20120093805 | ANTI-CD27 HUMANIZED MONOCLONAL ANTIBODY - The present invention provides a monoclonal antibody which specifically recognizes CD27 containing an O-linked sugar chain to which galactose is not bound and binds to its extracellular region, or a method for using the same. The present invention can provide a monoclonal antibody or an antibody fragment thereof, which specifically recognizes a polypeptide encoded by CD27 gene containing an O-linked sugar chain to which galactose is not bound, and binds to its extracellular region; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which comprises the DNA; a transformant obtainable by transforming the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a diagnostic agent or a therapeutic agent comprising the antibody or the antibody fragment thereof as an active ingredient. | 2012-04-19 |
20120093806 | ANTITUMOR COMBINATIONS CONTAINING ANTIBODIES RECOGNIZING SPECIFICALLY CD38 AND CYTARABINE - Pharmaceutical composition comprising an antibody specifically recognizing CD38 and cytarabine. | 2012-04-19 |
20120093807 | ROR ALPHA PROMOTING THE INDUCTION OF BMALL - An object of the present invention is to clarify unelucidated aspects in the control mechanism of circadian rhythms. The present inventors have newly found that RORα (retinoic acid binding-receptor alpha; the same shall apply hereinafter) stimulates an induction of Bmal1 expression and also that the induction of Bmal1 expression is promoted under hypoxia. These findings strongly suggest the existence of a control mechanism of circadian rhythms that, when RORα expression is promoted under hypoxia or the like, an induction of Bmal1 expression is stimulated and, when the induction of Bmal1 expression is stimulated, binding between BMAL1 and CLOCK is stimulated and an induction of Per gene or Cry gene expression is stimulated. The present invention, therefore, has applicability as jet-lag regulating agents and anticancer agents. | 2012-04-19 |
20120093808 | HUMANIZED PCRV ANTIBODY HAVING ANTI-PSEUDOMONAL ACTIVITY - Provided are a humanized monoclonal antibody against PcrV or a part thereof, and a pharmaceutical composition containing the same as an active ingredient, as an effective means for therapy of infection, particularly infection with | 2012-04-19 |
20120093809 | USE OF ALKANOYL L-CARNITINE IN COMBINATION WITH CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF NEOPLASMS - The present invention relates to the use of an alkanoyl L-carnitine selected from the group consisting of acetyl, propionyl, valeryl, isovaleryl and butirryl L-carnitine; in combination with one or more chemotherapeutic agent selected from the group consisting of: a camptothecin derivative; an alkylating agent; an anti-neoplastic anti-metabolite; a platin compound; a topoisomerase inhibitor; a VEGF inhibitor; a tyrosine kinase inhibitor; an EGFR kinase inhibitor; an mTOR kinase inhibitor; an insulin-like growth factor I inhibitor; a Raf kinase inhibitor; a monoclonal antibody; a proteasome inhibitor; a HDAC inhibitor; toxins; and imides; for the treatment of neoplasms. | 2012-04-19 |
20120093810 | MONOCLONAL ANTIBODY CAPABLE OF BINDING TO SPECIFIC DISCONTINUOUS EPITOPE OCCURRING IN AD1 REGION OF HUMAN CYTOMEGALOVIRUS GB GLYCOPROTEIN, AND ANTIGEN-BINDING FRAGMENT THEREOF - The present invention provides a pharmaceutical composition for human cytomegalovirus HCMV causative of various disease states, the composition comprising a monoclonal antibody and an antigen-binding fragment thereof that specifically binds to the AD1 region of glycoprotein gB and that has excellent neutralizing capacity. The present invention provides: a monoclonal antibody and an antigen-binding fragment thereof having an excellent neutralizing capacity and cell-to-cell infection blocking capacity and specifically binding to a discontinuous sequence occurring in the HCMV AD1 region; a pharmaceutical composition comprising the antibody or the fragment thereof; and the like. | 2012-04-19 |
20120093811 | ANTI-VEGF-D ANTIBODIES - The invention relates to an isolated antibody that specifically binds vascular endothelial growth factor-D (VEGF-D) and to a humanized antibody that specifically binds VEGF-D. | 2012-04-19 |
20120093812 | Method of Treating Degenerative Disorders of the Nervous System - The invention herein related to methods and compositions for treating nervous system disorders. The methods comprise administration of antibodies directed towards peptides that bind to receptors important in disease progression, thus attenuating the disease. | 2012-04-19 |
20120093813 | ANTI NOTCH-1 ANTIBODIES - This invention is directed toward monoclonal antibodies that bind specifically to Notch1. In one embodiment, the antibodies binds to at least a first epitope and a second epitope, wherein the first epitope resides with the LinA domain of the Notch1 negative regulatory region (NRR), and the second epitope resides within the HD-C domain of the Notch1 NRR. | 2012-04-19 |
20120093814 | Fusion Proteins Comprising Canine FC Portions - The present invention relates to therapeutic peptides and proteins fused to a canine antibody Fc domain. Methods and compositions of using the same are described. | 2012-04-19 |
20120093815 | FGF21 MUTANTS AND USES THEREOF - The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions. | 2012-04-19 |
20120093816 | Use of TNF-alpha Inhibitors for Treating a Nerve Disorder Mediated by Nucleus Pulposus - The present invention relates to a method and a pharmaceutical composition for treatment of nerve disorders comprising administration of a therapeutically effective dosage of at least two substances selected from the group consisting of TNF inhibitors, IL-1 inhibitors, IL-6 inhibitors, IL-8 inhibitors, FAS inhibitors, FAS ligand inhibitors, and IFN-gamma inhibitors. Preferably, at least one of the substances is a TNF inhibitor. | 2012-04-19 |
20120093817 | USE OF THE GENES IN THE HOG, Ras AND cAMP PATHWAY FOR TREATMENT OF FUNGAL INFECTION - Provided herein are uses of genes for HOG, Ras and cAMP signal transduction pathways to treat fungal infection. To regulate the HOG pathway of | 2012-04-19 |
20120093818 | ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9) - Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described. | 2012-04-19 |
20120093819 | ANTIBODIES THAT SPECIFICALLY BLOCK THE BIOLOGICAL ACTIVITY OF A TUMOR ANTIGEN - Novel monoclonal antibodies that specifically bind to KAAG1 are described. In some embodiments, the antibodies block the biological activity of KAAG1 and are useful in composition in certain cancers, more particularly in cancers that have increased cell surface expression of KAAG1, such as ovarian, renal, lung, colorectal, breast, brain, and prostate cancer, as well as melanoma. The invention also relates to cells expressing the monoclonal antibodies and antigen binding fragments such as humanized and chimeric antibodies. Additionally, method of detecting and treating cancer using the antibodies and fragments are also disclosed. | 2012-04-19 |
20120093820 | Prostatitis-Associated Antigens and Methods of Use Thereof - The present disclosure provides prostatitis-associated antigens, and compositions comprising the antigens. The present disclosure provides diagnostic methods, generally involving assaying the level of an immune response specific for a prostatitis-associated antigen in an individual. Kits suitable for use in performing such diagnostic assays are also provided. The present disclosure further provides methods of treating prostatitis, methods of treating prostate cancer, and methods of treating benign prostatic hyperplasia. | 2012-04-19 |
20120093821 | PAPILLOMAVIRUS-LIKE PARTICLES (VLP) AS BROAD SPECTRUM HUMAN PAPILLOMAVIRUS (HPV) VACCINES - This invention relates, e.g., to a virus-like particle (VLP) composition assembled from a chimeric polypeptide comprising a papilloma virus (e.g., human papillomavirus, or HPV) L1 major capsid protein, into which is inserted a surface-displayed peptide comprising a neutralizing epitope of a papillomavirus L2 protein. Vaccine compositions comprising the VLP are described, as well as methods for inducing an immune response (e.g., vaccinating) a subject against papilloma virus, using the VLP, and kits comprising the VLP, for carrying out a method of the invention. | 2012-04-19 |
20120093822 | DOPAMINE D2 RECEPTOR-DISC1 INTERACTION, COMPOSITIONS AND METHODS FOR MODULATING SAME - The present invention provides compounds, compositions and methods for inhibiting D2R-DISC1 interaction. Specifically, the present invention provides a polypeptide comprising the amino acid sequence KIYIVLRRRRKRVNT (SEQ ID NO: 1) or SEQ ID NO:5, a fragment thereof, or a polypeptide comprising an amino acid sequence that is at least 80% identical to SEQ ID NO: 1 or 5, or a fragment thereof, wherein the polypeptide is not a naturally occurring dopamine receptor. Also provided is a method of identifying an agent that inhibits the interaction of D2R with DISC1, a method of identifying an agent that binds to the polypeptide sequence defined by SEQ ID NO: 1 or 5, and a method of inhibiting D2R interaction with DISC1 in a mammal comprising administering an agent that inhibits the interaction of D2R with DISC1 to the mammal. | 2012-04-19 |
20120093823 | HUMAN BINDING MOLECULES CAPABLE OF NEUTRALIZING INFLUENZA VIRUS H5N1 AND USES THEREOF - Described are binding molecules such as human monoclonal antibodies that bind to influenza virus H5N1 and have neutralizing activity against influenza virus H5N1. Also described are nucleic acid molecules encoding the antibodies, and compositions comprising the antibodies and methods of identifying or producing the antibodies. The antibodies can be used in the diagnosis, prophylaxis, and/or treatment of an influenza virus H5N1 infection. In certain embodiments, the antibodies provide cross-subtype protection in vivo, such that infections with H5, H2, H6, H9, and H1-based influenza subtypes can be prevented and/or treated. | 2012-04-19 |
20120093824 | METHODS FOR TREATING PRURITUS BY ADMINISTERING AN ANTIBODY THAT SPECIFICALLY BINDS HUMAN PAR2 - The present invention provides methods for treating pruritus by blocking human protease activated receptor-2 (PAR2) activity. The methods of the invention can be used to treat pruritus associated with atopic dermatitis, psoriasis, burn scarring, hypertrophic scarring, keloids, renal failure or hepatic failure. The methods of the invention include administering an antibody or antigen-binding fragment thereof that specifically binds human PAR2. | 2012-04-19 |
20120093825 | METHOD FOR PRODUCING ANTIBODY USING "NAKED" EXPRESSION VECTOR EXPRESSING TYPE II TRANSMEMBRANE FUSION PROTEIN - Methods are disclosed for generating antibodies and an expression vector used to express protein(s) which provoke the antibody response. The expression vector may be useful in generating an antibody directed to an antigen, comprising a gene in operable linkage with a promoter, which gene encodes upon expressing a fusion protein comprising (i) CD134L, a fragment or homologous protein thereof as N-terminal moiety of the fusion protein; and (ii) all or part of an antigenic protein as C-terminal moiety of the fusion protein. To generate the antibodies, the vector is injected into a subject animal, which produces a fusion protein, against which antibodies are generated. | 2012-04-19 |
20120093826 | FULLY HUMAN ANTIBODIES SPECIFIC TO CADM1 - The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, more particularly engineered antibodies resulting in increased binding to Fc receptors and/or increased potency for ADCC or immunoconjugates, which specifically bind to CADM1 with high affinity. Nucleic acid molecules encoding CADM1 antibodies, expression vectors, host cells and methods for expressing the CADM1 antibodies are also provided. Bispecific molecules and pharmaceutical compositions comprising the CADM1 antibodies are also provided. Methods for detecting CADM1, as well as methods for treating various cancers, including lung cancer and pancreatic cancer, are disclosed. | 2012-04-19 |
20120093827 | TREATMENT OF AUTOIMMUNE DISORDERS WITH A NEUROTOXIN - Methods of treating one or more autoimmune disorders include a step of administering a Clostridial neurotoxin, such as a | 2012-04-19 |
20120093828 | VACCINE COMPOSITIONS AND METHODS FOR TREATMENT OF MUCORMYCOSIS AND OTHER FUNGAL DISEASES - The present invention provides therapeutic compositions and methods for treating and preventing fungal disease or conditions including mucormycosis. The therapeutic methods and compositions of the invention include vaccine compositions having an FTR polypeptide or an antigenic fragment of the polypeptide; a vector including a nucleotide sequence that is substantially complimentary to at least 18 contiguous nucleotides of FTR sequence; an antisense; a small interfering RNA or an antibody inhibitor of FTR. The vaccine compositions of the invention can further include an adjuvant. | 2012-04-19 |
20120093829 | NEW METHODS FOR TREATMENT OF INFLAMMATORY DISEASES - It provides methods and pharmaceutical compositions comprising antagonists to the protein Bile Salt-Stimulated Lipase (BSSL) for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis. It further relates to pharmaceutical compositions comprising BSSL antagonists and their use in methods for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis. Suitable BSSL antagonists to be used according to the invention are BSSL antibodies. | 2012-04-19 |
20120093830 | SINGLE DOMAIN ANTIBODIES THAT BIND IL-13 - Disclosed are ligands that have binding specificity for interleukin-13 (IL-13), or for IL-4 and IL-13. Also disclosed are methods of using these ligands. In particular, the use of these ligands for treating allergic asthma is described. | 2012-04-19 |
20120093831 | METHODS AND MATERIALS FOR MODULATING RESISTANCE TO APOPTOSIS - This document provides methods and materials involved in modulating a cell's ability to be resistant to apoptosis. For example, methods and materials for exposing cells to KLK6 polypeptides, or increased KLK6 polypeptide activity, to promote resistance to apoptosis are provided. In addition, methods and materials for reducing the ability of KLK6 polypeptides to promote resistance to apoptosis are provided. | 2012-04-19 |
20120093832 | PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS - The invention relates to the treatment of diseases or disorders of the nervous system. In particular, the invention relates to the treatment of diseases or disorders of the nervous system by stem cell therapy, in particular therapy with neural precursor cells. In preferred aspects of the invention, inhibitors of chemoattraction are administered prior to, concomitantly with, or subsequently to the administration of neural precursor cells. | 2012-04-19 |
20120093833 | Human Oncostatin M Antibodies and Methods of Use - Antibodies and compositions capable of neutralizing oncostatin M biological functions are useful in treating diseases and disorders associated with oncostatin M, such as osteoarthritis and idiopathic pulmonary fibrosis. | 2012-04-19 |
20120093834 | NEUTRALIZING MOLECULES TO VIRAL ANTIGENS - The present invention concerns methods and means for identifying, producing, and engineering neutralizing molecules against influenza A viruses, and to the neutralizing molecules produced. In particular, the invention concerns neutralizing molecules against various influenza A virus subtypes, including neutralizing antibodies against H5 and/or H3 and/or H1, such as, for example all of H1, H3, and H5 subtypes, and methods and means for making such molecules. | 2012-04-19 |
20120093835 | ANTI-INFLAMMATORY ANTIBODIES AND USES THEREFOR - The invention provides antibodies that inhibit activation of complement, which may be used to treat various inflammatory diseases or disorders. | 2012-04-19 |
20120093836 | PHARMACEUTICAL COMPOSITIONS FOR TREATING METASTASIS - The present invention relates to the use of an antifungal agent or of a compound capable of binding to a mannoprotein and blocking the binding of said mannoprotein to an endothelial cell receptor, in the preparation of a pharmaceutical composition for treating a disease associated to an unwanted cell adhesion. Likewise, the present invention also contemplates methods aimed at identifying a compound potentially useful for preventing and/or treating a disease associated to an unwanted cell adhesion, for predicting the probability of a patient suffering from cancer to suffer from metastasis and for designing a personalized therapy for a patient suffering from cancer. | 2012-04-19 |
20120093837 | COMPOSITIONS AND METHODS FOR DETECTING EGFR IN CANCER - The invention discloses binding agents to the E746-A750 deletion and the L858R point mutations in the epidermal growth factor receptor (EGFR) molecule, and methods for use thereof, including methods for the diagnosis and treatment of cancer. | 2012-04-19 |
20120093838 | GENE DETECTION ASSAY FOR IMPROVING THE LIKELIHOOD OF AN EFFECTIVE RESPONSE TO A HER2 ANTIBODY CANCER THERAPY - The invention provides a method for more effective treatment of patients susceptible to or diagnosed with tumors overexpressing HER2, as determined by a gene amplification assay, with a HER2 antibody. Such method comprises administering a cancer-treating dose of the HER2 antibody, preferably in addition to chemotherapeutic agents, to a subject in whose tumor cells her2 has been found to be amplified e.g., by fluorescent in situ hybridization. | 2012-04-19 |
20120093839 | NOVEL ANTIGEN BINDING DIMER-COMPLEXES, METHODS OF MAKING/AVOIDING AND USES THEREOF - In a broad aspect the present invention generally relates to novel dimer-complexes (herein called “non-fused-dimers” or NFDs) comprising single variable domains, methods of making these complexes and uses thereof. These non-covalently bound dimer-complexes consist of two identical monomers that each comprises of one or more single variable domains (homodimers) or of two different monomers that each comprises on or more single variable domains (heterodimers). The subject NFDs have typically altered e.g. improved binding characteristics over their monomelic counterpart. The NFDs of the invention may further be engineered through linkage by a flexible peptide or cysteines in order to improve the stability. This invention also describes conditions under which such NFDs are formed and conditions under which the formation of such dimers can be avoided. | 2012-04-19 |
20120093840 | TARGETED DELIVERY OF FACTOR VIII PROTEINS TO PLATELETS - The invention described herein relates to novel molecules and polypeptides comprising at least one amino acid sequence having significant identity with (homology to) human Factor VIII or biologically active portion(s) thereof, related molecules (such as nucleic acids encoding such polypeptides), compositions (such as pharmaceutical formulations) comprising such polypeptides, and methods of making and using such polypeptides. | 2012-04-19 |
20120093841 | Her2 DNA Vaccine as Adjunct Treatment for Cancers in Companion Animals - The application discloses therapeutic vaccines based upon the “pING” DNA plasmid vector expressing the gene encoding the rat Her2 protein. Vaccines according to the instant disclosure are used as an adjunct treatment for surgery, radiation and/or chemotherapy for dogs and cats with cancers that over express the Her2 antigen, and prolong the post-surgical disease free interval and/or survival time. Also included are therapeutically effective methods of immunization using said vaccines. | 2012-04-19 |
20120093842 | CHIMERIC RECEPTOR GENES AND CELLS TRANSFORMED THEREWITH - Chimeric receptor genes suitable for endowing lymphocytes with antibody-type specificity include a first gene segment encoding a single-chain Fv domain of a specific antibody and a second gene segment encoding all or part of the transmembrane and cytoplasmic domains, and optionally the extracellular domain, of an immune cell-triggering molecule. The chimeric receptor gene, when transfected to immune cells, expresses the antibody-recognition site and the immune cell-triggering moiety into one continuous chain. The transformed lymphocytes are useful in therapeutic treatment methods. | 2012-04-19 |
20120093843 | TEM8 PEPTIDES AND VACCINES COMPRISING THE SAME - According to the present invention, peptides comprising the amino acid sequence of SEQ ID NO: 3, 4, 9, 23, 25, 30, 60, 63 or 68 were demonstrated to have cytotoxic T lymphocyte (CTL) inducibility. Therefore, the present invention provides a peptide having the amino acid sequence selected from the group of SEQ ID NOs: 3, 4, 9, 23, 25, 30, 60, 63 and 68. The peptide can include one, two, or several amino acid substitutions or addition so long as its CTL inducibility is retained. Furthermore, the present invention provides pharmaceutical agents for treating and/or prophylaxis of tumors, and/or prevention of postoperative recurrence thereof, which comprises any of these peptides. The pharmaceutical agents of this invention include vaccines. | 2012-04-19 |
20120093844 | ANTIMICROBIAL PEPTIDES BASED ON CMAP27 - The invention concerns derivatives of CMAP27, which have a good antimicrobial activity and a low haemolytic activity as compared to the wild-type CMAP27 peptide. These derivatives can be used for antibiotic therapy or in a bacteriocidal composition. Further comprised in the invention is the use of CMAP27 and/or its derivatives as adjuvant. | 2012-04-19 |
20120093845 | NEIL3 PEPTIDES AND VACCINES INCLUDING THE SAME - The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 45, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences. The invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for diagnosing or treating cancer. | 2012-04-19 |
20120093846 | PROTEIN FOR THE IMMUNOCASTRATION FOR MAMMALS - Fusion protein for immunocastration (Sequences 1a and 1b) that comprises the primary amino acid sequence of the gonadotrophin-liberating protein fused to a theoretical sequence: | 2012-04-19 |
20120093847 | RECOMBINANT RSV VACCINES - This disclosure provides recombinant respiratory syncytial virus (RSV) antigens and methods for making and using them, including immunogenic compositions (e.g., vaccines) for the treatment and/or prevention of RSV infection. | 2012-04-19 |
20120093848 | IMMUNOGENIC COMPOSITION COMPRISING PEPTIDES DERIVED FROM CYTOMEGALOVIRUS AND THE USE THEREOF - The present invention provides (poly)peptides, which are recognized by human cytomegalovirus (CMV)-specific immune cells. The present invention further provides a combination of multiple CMV (poly)peptides, comprising at least two different groups of (poly)peptides according to the invention as well as conjugates, comprising said (poly)peptides and/or immune adjuvants thereof. Furthermore, this invention provides mixtures, comprising said (poly)peptides and/or immune cells thereof, which are used to generate CMV-specific immune effector cells with high sensitivity and specificity. In addition, the present invention provides a preparation method of CMV-specific immune effector cells, by using said (poly)peptides, adjuvants, immune cells and/or mixtures thereof to generate anti-CMV immune response. | 2012-04-19 |
20120093849 | Agents for Treatment of HCV and Methods of Use - An amphipathic helix at the approximate N-terminus of Hepatitis C virus (HCV) nonstructural proteins mediates the association of these proteins with cytoplasmic membranes in infected cells. This association is essential for replication. Thus, assessing the ability of compounds or protocols to disrupt the association of such helices with cytoplasmic membranes permits identification of compounds and protocols which are useful in the treatment of HCV infection. Also useful in the invention are mimics, or function-disrupting ligands, of an amphipathic helix of the nonstructural proteins described herein and antibodies and fragments thereof immunoreactive with said helix. | 2012-04-19 |
20120093850 | COMPOSITIONS FOR IMMUNISING AGAINST STAPHYLOCOCCUS AUREUS - Hla polypeptides having various deletions, insertions, and/or mutations which are useful for immunisation are provided herein. Also provided herein are Hla heptamers which are non-haemolytic. Additionally, an effective | 2012-04-19 |
20120093851 | CHLAMYDIA ANTIGENS - The invention provides | 2012-04-19 |
20120093852 | NON-LIPIDATED VARIANTS OF NEISSERIA MENINGITIDIS ORF2086 ANTIGENS - The present invention relates to compositions including an isolated non-pyruvylated non-lipidated ORF2086 polypeptide, and methods thereof. In an exemplary embodiment, the compositions described herein are immunogenic. The present invention further relates to compositions that elicit a bactericidal immune response in a mammal against an ORF2086 subfamily B polypeptide from serogroup B | 2012-04-19 |
20120093853 | Simian Adenovirus Vectors and Methods of Use - A recombinant vector comprises a simian adenovirus capsid and a heterologous gene under the control of regulatory sequences. A cell line which expresses simian adenovirus gene(s) is also disclosed. Methods of using the vectors and cell lines are provided. | 2012-04-19 |
20120093854 | USE OF MYCOPLASMA BOVIS ANTIGEN - The present invention relates to combination vaccines and/or the combined use of immunogenic compositions for the treatment and/or prophylaxis of cattle against microbiological infections, wherein the infections are caused by | 2012-04-19 |
20120093855 | RSV F VLPs AND METHODS OF MANUFACTURE AND USE THEREOF - The present invention relates to the field of isolation of enveloped virus-based virus-like particles (VLPs) free of infectious agents. In preferred examples, the field includes methods of inactivation of infectious agents that do not adversely affect the immunogenicity of the enveloped virus-based VLPs. In certain embodiments, the enveloped virus-based VLPs are produced in insect cell based expression systems. | 2012-04-19 |
20120093856 | METHODS FOR USING EXTRACELLULAR ADENOSINE INHIBITORS AND ADENOSINE RECEPTOR INHIBITORS TO ENHANCE IMMUNE RESPONSE AND INFLAMMATION - A method is provided herein to increase an immune response to an antigen. The method includes administering an agent that inhibits extracellular adenosine or inhibits adenosine receptors. Also disclosed are methods to increase the efficacy of a vaccine and to increase an immune response to a tumor antigen or immune cell-mediated tumor destruction. | 2012-04-19 |
20120093857 | Vaccination and Immunotherapy as New Therapeutic Modalities in the Treatment of Glaucoma - This invention provides a method whereby a vaccine, particularly a vaccine based on a prophylactic or therapeutic AIDS/HIV vaccine, or other immune-reactive substance is administered to produce an immunologic response that decreases intraocular pressure or has a neuro-protective effect beneficial in the treatment of glaucoma patients. The invention may also be used as a provocative test to diagnose glaucoma as well as identify those patients at risk for developing glaucoma. The invention may also be used to prevent the development of glaucoma in patients deemed to be at high risk of developing glaucoma, such as glaucoma suspects or ocular hypertensive patients. | 2012-04-19 |
20120093858 | Tat-Based Tolerogen Compositions and Methods for Making and Using Same - A Tat-based tolerogen composition comprising at least one immunogenic antigen coupled to at least one human immunodeficiency virus (HIV) trans-activator of transcription (Tat) molecule wherein the immunogenic antigen can be a foreign or endogenous antigen or fragments thereof. Additionally methods of suppressing organ transplant rejection and methods of treating autoimmune diseases are provided. | 2012-04-19 |
20120093859 | INFLUENZA VACCINE REGIMENS FOR PANDEMIC-ASSOCIATED STRAINS - In contrast to known regimens where pandemic-associated antigens are given 3-4 weeks apart for immunisation, according to the invention two doses of a pandemic-associated antigen are administered to a human 1 week apart, 2 weeks apart or 6 weeks apart. Thus the invention provides a method for immunizing a human, comprising steps of: (a) administering to the human a first vaccine comprising antigen from a pandemic-associated influenza virus strain; and then 1/2/6 week(s) later, (b) administering to the same human a second influenza vaccine comprising antigen from the pandemic-associated influenza virus strain. | 2012-04-19 |
20120093860 | INFLUENZA VACCINES WITH INCREASED AMOUNTS OF H3 ANTIGEN - An influenza vaccine includes an increased amount of H3N2 antigen relative to the normal dose. In a typical embodiment, the vaccine includes hemagglutinins from an A/H1N1 strain, an A/H3N2 strain, and a B strain, wherein (i) the weight ratio of H3N2:H1N1 hemagglutinin is greater than 1 and (ii) the weight ratio of H3N2:B hemagglutinin is greater than 1. In such a vaccine the weight ratio of H1N1:B hemagglutinin will normally be 1. For example, a vaccine may contain hemagglutinin at 15 μg for A/H1N1, 30 μg for A/H3N2 and 15 μg for B. | 2012-04-19 |
20120093861 | NOROVIRUS VACCINE FORMULATIONS - The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups. | 2012-04-19 |
20120093862 | NUCLEIC ACID VACCINES FOR PREVENTION OF FLAVIVIRUS INFECTION - The invention encompasses nucleic acid molecules containing transcription units which encode the flavivirus M and E protein antigens. The flaviviruses include Japanese encephalitis virus, dengue, yellow fever virus and St. Louis encephalitis virus. The nucleic acids function to provide the M and E protein antigens when the nucleic acid resides in an appropriate host cell, especially when the host cell is the cell of a subject. The invention also encompasses a vaccine whose active agent is the nucleic acid. The invention further encompasses the cultured host cells when they contain within them nucleic acid molecules containing the transcription units. The invention in addition encompasses a method of immunizing a subject against flavivirus infection by administering to the subject an effective amount of a vaccine containing a nucleic acid molecule containing the transcription unit of the invention. | 2012-04-19 |
20120093863 | HCV VACCINES AND METHODS FOR USING THE SAME - Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1a, including for example, NS4B, NS5A and NS5B. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HCV are disclosed. | 2012-04-19 |
20120093864 | Methods and Compositions for Polytopic Vaccination - The present invention relates to therapeutic and prophylactic methods for treating Or preventing an infectious disease in a subject by stimulating or enhancing an immune response against an infectious agent causing the disease. The methods comprise administering to the subject a plurality of compositions, each composition being administered to a different site Of the subject, wherein each site is, or substantially drains to, an anatomically distinct lymph node, a group of lymph nodes, a nonencapsulated cluster of lymphoid tissue, or the spleen. Each composition comprises at least one antigenic molecule having one or more epitopes of the same infectious agent or a strain thereof. The antigenic molecules of each composition comprise in aggregate a set of epitopes distinct from that of any other composition that is administered to the subject. | 2012-04-19 |
20120093865 | COMPOSITIONS COMPRISING REDUCED GENOME BACTERIA FOR USE IN TREATMENT OF SEPSIS - Methods for prophylaxis or treatment of sepsis in a subject are provided comprising administering to the subject a therapeutically effective dose of multiple deletion strain bacteria. | 2012-04-19 |
20120093866 | FORMULATION FOR STABILIZING PROTEINS, WHICH IS FREE OF MAMMALIAN EXCIPIENT - The present invention pertains to a formulation comprising a hydrophilic polymer, a mixture of a polyalcohol and a sugar, wherein the weight ratio of polyalcohol to sugar is between 2:1 to 5:1 (wt-%), a detergent, and wherein the formulation is free of stabilizing proteins. | 2012-04-19 |
20120093867 | GNA1870-Based Vesicle Vaccines for Broad Spectrum Protection Against Diseases Caused by Neisseria Meningitidis - The present invention generally provides methods and compositions for eliciting an immune response against | 2012-04-19 |
20120093868 | HAEMOPHILUS INFLUENZAE TYPE B - Polypeptides comprising various amino acid sequences derived from | 2012-04-19 |